Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high fat diet-induced steatosis in IL-6 deficient mice
Authors:
- Ana Luisa GavitoAGAna Luisa Gavito
- Francisco Javier PavónFrancisco Javier Pavón
- Dolores BautistaDBDolores Bautista
- Antonia SerranoASAntonia Serrano
- Juan SuarezJSJuan Suarez
- Sergio ArrabalSASergio Arrabal
- Juan DecaraJDJuan Decara
- Miguel Romero-CuevasMiguel Romero-Cuevas
- Fernando Rodríguez de FonsecaFFFernando Rodríguez de Fonseca
- Elena BaixerasEBElena Baixeras
Open Access
- 1 January 2015
- journal article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 8 (7) , 721-731
Abstract
Interleukin-6 (IL-6) has emerged as an important mediator of fatty acid metabolism with paradoxical effects in the liver. Administration of IL-6 has been reported to confer protection against steatosis, but plasma and tissue IL-6 concentrations are elevated in chronic liver diseases, including fatty liver diseases associated with obesity and alcoholic ingestion. In this study, we further investigated the role of IL-6 on steatosis induced through a high-fat diet (HFD) in wild-type (WT) and IL-6-deficient (IL-6−/−) mice. Additionally, HFD-fed IL-6−/− mice were also chronically treated with recombinant IL-6 (rIL-6). Obesity in WT mice fed a HFD associated with elevated serum IL-6 levels, fatty liver, upregulation of carnitine palmitoyltransferase 1 (CPT1) and signal transducer and activator of transcription-3 (STAT3), increased AMP kinase phosphorylation (p-AMPK), and downregulation of the hepatic lipogenic enzymes fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1). The HFD-fed IL-6−/− mice showed severe steatosis, no changes in CPT1 levels or AMPK activity, no increase in STAT3 amounts, inactivated STAT3, and marked downregulation of the expression of acetyl-CoA carboxylase (ACCα/β), FAS and SCD1. The IL-6 chronic replacement in HFD-fed IL-6−/− mice restored hepatic STAT3 and AMPK activation but also increased the expression of the lipogenic enzymes ACCα/β, FAS and SCD1. Furthermore, rIL-6 administration was associated with aggravated steatosis and elevated fat content in the liver. We conclude that, in the context of HFD-induced obesity, the administration of rIL-6 might contribute to the aggravation of fatty liver disease through increasing lipogenesis.Keywords
This publication has 53 references indexed in Scilit:
- Genetic control ofde novolipogenesis: role in diet-induced obesityCritical Reviews in Biochemistry and Molecular Biology, 2010
- Activation of AMP-Activated Protein Kinase by Interleukin-6 in Rat Skeletal MuscleDiabetes, 2009
- Nonalcoholic fatty liver disease and nonalcoholic steatohepatitisHepatology, 2008
- Dual Role of Interleukin-6 in Regulating Insulin Sensitivity in Murine Skeletal MuscleDiabetes, 2008
- Inflammation and metabolic disordersNature, 2006
- Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistanceJournal of Clinical Investigation, 2006
- Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout miceHepatology, 2004
- Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinaseBiochemical Society Transactions, 2002
- STIMULATION OF LIPOGENESIS BY INTERLEUKIN-6 AND MISOPROSTOL-FREE ACID IN ISOLATED RAT HEPATOCYTES†American Journal of Therapeutics, 1995
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959